Jade Biosciences, INC. (JBIO) — 8-K Filings

All 8-K filings from Jade Biosciences, INC.. Browse 22 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (22)

8-K Filing — Apr 22, 2026
8-K Filing — Dec 15, 2025
Jade Biosciences Files 8-K with Material Agreements and Disclosures — Oct 7, 2025 Risk: medium
On October 3, 2025, Jade Biosciences, Inc. filed an 8-K report detailing several key events. The company entered into a Material Definitive Agreement, reported
Jade Biosciences Reports Director and Officer Changes — Sep 9, 2025 Risk: low
On September 5, 2025, Jade Biosciences, Inc. (formerly Aerovate Therapeutics, Inc.) filed an 8-K report detailing changes in its board of directors and executiv
Jade Biosciences Announces Board Changes and Material Agreement — Jul 1, 2025 Risk: medium
On June 25, 2025, Jade Biosciences, Inc. announced the departure of two directors, Dr. David Epstein and Mr. David M. R. Gray, and the appointment of two new di
Jade Biosciences Files 8-K on Asset Disposition — May 14, 2025 Risk: medium
On May 14, 2025, Jade Biosciences, Inc. (formerly Aerovate Therapeutics, Inc.) filed an 8-K report. The filing indicates a completion of acquisition or disposit
Jade Biosciences Files 8-K with Major Corporate Updates — May 1, 2025 Risk: medium
Jade Biosciences, Inc. (formerly Aerovate Therapeutics, Inc.) filed an 8-K on May 1, 2025, reporting several material events as of April 28, 2025. These include
Aerovate Therapeutics Files 8-K — Apr 29, 2025 Risk: low
Aerovate Therapeutics, Inc. filed an 8-K on April 29, 2025, reporting information under Regulation FD and including financial statements and exhibits. The compa
Aerovate Therapeutics Files 8-K Report — Apr 23, 2025 Risk: low
On April 23, 2025, Aerovate Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events." No spec
Aerovate Therapeutics Files 8-K — Apr 21, 2025 Risk: low
Aerovate Therapeutics, Inc. filed an 8-K on April 21, 2025, reporting on events that occurred on April 16, 2025. The filing indicates matters submitted to a vot
Aerovate Therapeutics Files 8-K — Apr 9, 2025 Risk: medium
Aerovate Therapeutics, Inc. filed an 8-K on April 9, 2025, reporting an "Other Event." The filing does not contain specific details about the event, dollar amou
Aerovate Therapeutics Files 8-K — Apr 7, 2025 Risk: low
Aerovate Therapeutics, Inc. filed an 8-K on April 7, 2025, reporting on other events and financial statements. The filing does not contain specific financial fi
Aerovate Therapeutics to be Acquired by InspireMD — Oct 31, 2024 Risk: medium
Aerovate Therapeutics, Inc. announced on October 30, 2024, that it entered into a definitive agreement to be acquired by InspireMD Ltd. for approximately $23.5
Aerovate Therapeutics Faces Delisting Concerns — Oct 17, 2024 Risk: high
Aerovate Therapeutics, Inc. filed an 8-K on October 17, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The company's prin
Aerovate Therapeutics Announces Leadership Changes — Oct 10, 2024 Risk: medium
Aerovate Therapeutics, Inc. announced on October 6, 2024, the departure of its Chief Medical Officer, Dr. Lisa Rojkowska. The company also reported the election
Aerovate Therapeutics Files 8-K — Jul 8, 2024 Risk: low
On July 8, 2024, Aerovate Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific
Aerovate Therapeutics Reports Exit Costs — Jun 28, 2024 Risk: medium
On June 25, 2024, Aerovate Therapeutics, Inc. filed an 8-K report detailing costs associated with exit or disposal activities. The company, incorporated in Dela
Aerovate Therapeutics Terminates Merger with Hansoh Pharma — Jun 17, 2024 Risk: high
On June 17, 2024, Aerovate Therapeutics, Inc. filed an 8-K report detailing the termination of its merger agreement with Jiangsu Hansoh Pharmaceutical Group Co.
Aerovate Therapeutics Holds Shareholder Vote — Jun 7, 2024 Risk: low
Aerovate Therapeutics, Inc. filed an 8-K on June 7, 2024, reporting on a meeting held on June 5, 2024, where security holders voted on certain matters. The fili
Aerovate Therapeutics Files 8-K — May 13, 2024 Risk: low
Aerovate Therapeutics, Inc. filed an 8-K on May 13, 2024, reporting on its results of operations and financial condition. The filing includes financial statemen
Aerovate Therapeutics Files 8-K Report — Mar 27, 2024 Risk: low
On March 27, 2024, Aerovate Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corporat
Aerovate Therapeutics Files Routine 8-K on Jan 8, 2024 — Jan 8, 2024
Aerovate Therapeutics, Inc. filed an 8-K on January 8, 2024, to disclose information under Regulation FD and provide financial statements and exhibits. This fil

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX